Preliminary studies in animal models of heart failure have suggested that a more beneficial blockade of angiotensin II can be accomplished by combining the effects of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB).3 These observations have led to the design of several clinical trials to ascertain whether the combination of an ARB and an ACE inhibitor might be beneficial for clinical outcomes in patients with CHF.4-7. The gene discussed is ACE; the disease is heart failure.